Clinical Trial Update: Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

View source ↗

Summary

This trial update reports the prevalence of osteoporosis among Korean prostate cancer patients treated with LHRH agonists and/or anti-androgen agents. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Prostate Cancer

Drugs mentioned

• Anti-androgen agent (Anti-androgen)
• LHRH agonist (Gonadotropin-releasing hormone (GnRH) agonist)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer, Osteoporosis | Status: COMPLETED